|Bid||55.29 x 800|
|Ask||61.00 x 1000|
|Day's Range||58.37 - 59.39|
|52 Week Range||54.17 - 71.04|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||13.01|
|Forward Dividend & Yield||1.64 (2.55%)|
|1y Target Est||N/A|
Bruce Wilpon, the Managing Partner of Mikkeller NYC brewery, talks to Yahoo Finance's Brian Sozzi and Alexis Christoforous about the overall state of the beer industry and his local brewery at New York Mets Citi Field. Wilpon also weighs in on hi hope to partner up with Uber Eats.
Today we'll take a closer look at Molson Coors Brewing Company (NYSE:TAP) from a dividend investor's perspective...
While it's not the best-known of the pot stocks, Hexo (NYSEAMERICAN:HEXO) is starting to build its reputation. Between fantastic year-to-date performance, a recent uplisting to a major U.S. stock exchange, and a shrewd merger, things are looking up for Hexo stock. There's also a promising venture with MolsonCoors (NYSE:TAP) that gives Hexo credibility and helps elevate it to the big leagues within the pot stock universe.Unfortunately, shareholders buying into the story today may be getting in a little late. The stock is up to more than $6 in just a few months. That, along with dilution from its recent merger has inflated Hexo's market cap a great deal. The company now has a lot to prove in order to justify its stock price.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) Hexo Has Huge AmbitionsA lot of marijuana companies are talking a big game about their future plans. More than a couple of the bigger companies seem intent on building global empires. Even by those standards, however, Hexo is shooting for the moon.On the company's most recent earnings conference call, CEO Sebastien St. Louis stated, "Our vision has remained consistent to create a branded consistent on and off cannabis experience across a variety of verticals in a variety of experiences ranging from sleep, to sport, to sex, to diet, to fun."Hexo isn't just aiming to sell marijuana, it wants to change everything ranging from sex to athletics and nutrition. Heady stuff.Furthermore, Hexo either sees the pot market becoming huge. Or perhaps it is planning on a variety of non cannabis things as well. To those ends, St. Louis said, "We intend to become the premiere branded ingredients for food companies not only a top two in Canada, but also top three globally."For comparison's sake, a U.S. leader in the ingredients for food space, Ingredion (NYSE:INGR) has both a market cap and annual sales of around $6 billion. Hexo, by contrast, has a market cap of under $2 billion and sold just ~$10 million of product last quarter. If Hexo can reach the size of a company like Ingredion, it'd be a home run for shareholders. But it has a long way to go to reach that aim. Can Hexo Live up to the Hype?Hexo stock is having a fantastic year. As of this writing, the stock is up 101% year to date. That's incredible on its own. It's even more impressive when you consider that most of the other leading marijuana stocks have been in a bit of a slump lately.We have to ask if Hexo will be able to maintain its hot streak though. As our Vince Martin recently wrote, much of Hexo's recent gains have come from investors discovering the stock, rather than the company's actual accomplishments."The story behind Hexo is gaining a broader reach -- and the Hexo stock price is responding in kind. The question at this point is whether that's a good thing -- and whether a strong YTD is starting to price in at least some of the opportunity here, "Martin wrote.Martin went on to explain how trading volume in HEXO stock has surged. In particular, with the company's up-listing to a major market in the U.S., it has attracted far more activity. But the company will now need to demonstrate that it can live up to its greatly increased share price. Newstrike Deal Looks Like a PositiveOne positive for Hexo, as compared to other marijuana companies, is that it acquired Newstrike Brands (OTCMKTS:NWKRF). Hexo appears to have gotten a great deal, as it paid just a few percent premium to Newstrike's then stock price. Newstrike removes one key limitation for Hexo. Remember that Hexo is based in Quebec and has taken a big lead in French-speaking Canada. However Quebec makes up just 8 million out of Canada's 37 million person population. Newcastle, with its business relationships in English-speaking provinces gives Hexo a major boost in becoming a national rather than just regional player.Additionally, as of Newcastle's latest filing, that company had a large cash position and few liabilities. Combine with Hexo, which recently raised money of its own, and the combined firm will have a great balance sheet with which to pursue further growth opportunities. Hexo Stock VerdictHexo has built itself a bit of a differentiated business model from many of the other large Canadian marijuana rivals. Its focus on both edibles and beverages via the MolsonCoors relationship should give it some cover from steadily sinking marijuana prices in the Canadian recreational marijuana market. And if the company's ambitions come anywhere close to playing out, Hexo stock should be a big winner.On top of that, the company's balance sheet and Newstrike deal should give it a lot of positive momentum through the rest of 2019. The company is looking at going from a revenue run rate that is currently around $40 million to something like four times that next year. Hexo should have some solid earnings releases coming in future quarters.While the company's story is promising, make sure you are comfortable with the risk before buying into Hexo stock at this price. It wouldn't surprise me at all if the stock dipped 20-30% in coming weeks, particularly if the general malaise in the pot stock sector continues.At the time of this writing, Ian Bezek owned TAP and INGR stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Up More Than 100% Already, It's Time to Take Profits on Hexo Stock appeared first on InvestorPlace.
Since their inception, marijuana stocks attracted significant attention. Due to both investment sentiment - and let's face it, raw emotions - the cannabis sector absolutely skyrocketed. But now, the segment is attracting attention for failing to live up to analysts' expectations. Is the honeymoon phase over for weed?Hardly! While cannabis firms have produced some disappointing results during earnings season, that's no reason to abandon them. For one thing, the resurgent U.S.-China trade war is incredibly favorable for marijuana stocks to buy. Prolonged tensions will almost surely cause us economic damage. An easy fix here is to legalize weed and fully open the door to a multi-billion dollar industry.Another reason to stay the course with marijuana stocks to buy is the medicinal-cannabis market. Currently, 33 states have legalized medical marijuana, which is indirectly an indictment against the pharmaceutical industry. As I've argued many times before, pharmaceuticals must take at least some responsibility for the opioid crisis. This story alone has converted many people who have realized the benefits of all-natural treatments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMoreover, medical marijuana is becoming a popular and potentially profitable exported good. We all know that progressive Europe is receptive to cannabis-based therapies. But more shocking is that conservative Asian countries notorious for their draconian anti-drug policies have demonstrated tolerance. Thailand became the first Southeast Asian country to legalize medical marijuana, while South Korea is the first East Asian country to jump onboard. * Top 7 Dow Jones Stocks of 2019 -- So Far No matter how you look at it, this development strongly benefits the "botanical" industry. Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB)Source: Shutterstock Aurora Cannabis (NYSE:ACB) recently issued its earnings results for the first quarter of 2019. Let's just say the print wasn't exactly great for ACB stock. Although Aurora Cannabis' net-revenue haul of 65.2 million CAD exceeded the year-ago quarter's tally by a country mile, it missed analysts' consensus target of 67.6 million CAD.Also a miss was earnings per share. Wall Street expected a loss of 4 cents per share, but Aurora instead delivered a loss of 16 cents. With such a wide gap, conventional wisdom dictates that you should avoid ACB stock.Actually, though, even if Aurora Cannabis hit its metrics with flying colors, I wouldn't pay much attention. Why? Because this is a marathon investment toward an unprecedented sector. As such, you'll find nearer-term noise. Ignore it.The key here is that the management is positioning itself for dominance in the lucrative medical-marijuana market. Its acquisition of Whistler Medical Marijuana indicates that the focus is on quality, not quantity. When weak marijuana stocks get flushed out, ACB will remain standing. Canopy Growth (CGC)Source: Shutterstock Undeniably, a motivating factor to buy shares of Canopy Growth (NYSE:CGC) is the company's international presence. Primarily, it puts up a strong showing in the European mainland. Currently, Canopy is pushing both westward and eastward in the region. However, the ultimate prize for CGC stock and others is the U.S. market.Of course, this is seemingly a pipe dream due to our country's (misguided) Schedule I classification of marijuana. Still, CGC stock jumped mid-April when Canopy announced a contingent offer to buy out Acreage Holdings (OTCMKTS:ACRGF). Canopy will pay $300 million upfront if the U.S. legalizes marijuana.Many botanical advocates argue that Schedule I is a relic of the ignorant and racist past. However, it's still federal law, which means cannabis firms in green-friendly states are still technically at risk. * 7 Stocks to Buy that Lost 10% Last Week But thanks to the U.S.-China trade war, I genuinely believe that full legalization is nearing reality. A prolonged conflict with the world's second-biggest economy will invariably hurt our own fiscal health. That's why the U.S. has to explore marijuana if they insist on playing hardball with China. If so, look for CGC stock to soar. Hexo (HEXO)Source: Shutterstock If you're like most folks who learned about marijuana stocks to buy late in the game, you're probably hesitant on exposing yourself to the top-tier names. After all, we see them splattered on investment headlines all over the internet. If that's you, you might want to check out Hexo (NYSEAMERICAN:HEXO).For starters, Hexo is an understated name. It generates interest, of course, but not nearly as much as the top dogs. I believe that benefits HEXO stock and is partially the reason why shares have steadily made robust gains. Year-to-date, the cannabis firm's equity is up over 113%.That said, HEXO stock has much more upside remaining over the long term. Renowned alcoholic beverage-maker Molson Coors Brewing (NYSE:TAP) has a partnership with Hexo to develop cannabidiol (CBD) infused, non-alcoholic drinks.CBD recently gained mainstream recognition because it offers the cannabis plant's health benefits, but without levering a negative psychoactive effect. In other words, the compound is a perfect gateway for consumers to try other cannabis-based products.This is a partnership that provides multiple natural synergies. Even though it's not quite a household name, you should put Hexo on your list of marijuana stocks to buy.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post The 3 Best Marijuana Stocks to Buy Right Now appeared first on InvestorPlace.
The case for cannabis producer Hexo (NYSE:HEXO) has been based in part on the idea that investors have missed the story. When pot stocks started taking off early last year, the HEXO stock price still languished.More recently, pot plays like Canopy Growth (NYSE:CGC) and Tilray (NASDAQ:TLRY) have dominated the headlines; Hexo seemed to get a fraction of the coverage of those peers.That's clearly starting to change. The story behind Hexo is gaining a broader reach -- and the Hexo stock price is responding in kind. The question at this point is whether that's a good thing -- and whether a strong YTD is starting to price in at least some of the opportunity here.InvestorPlace - Stock Market News, Stock Advice & Trading Tips HEXO Stock Price SoarsWhile cannabis stocks soared in 2018, HEXO mostly was left out of the gains. The stock gained just 5% for the year, as a rally that began in September quickly fizzled.It's been a different story in 2019. HEXO has gained 101% YTD as of this writing. And there are some fundamental reasons for the gains. The announced acquisition of Newstrike Brands (OTCMKTS:NWKRF) was well-received. Hexo raised cash at the beginning of the year, putting its balance sheet in good shape. Second-quarter results in March looked impressive: sales increased over 1,200%. * 7 Dividend Stocks to Buy as the Trade War Reignites But a big part of the story with HEXO stock in 2019 is that its story has spread. That's most apparent when looking at the stock's trading volume. At the end of last year, 30-day average daily volume was under 400,000 shares. Four and a half months later, it's at 5.3 million.The company's listing on the New York Stock Exchange has been a huge driver of that volume. And it's helped the HEXO story become more widely known. That, along with the Newstrike deal and the strong Q2, has been why HEXO stock has outperformed other pot stocks.CGC shares are up 70% so far this year, and Aurora Cannabis (NYSE:ACB) about the same. (Interestingly, an NYSE listing had the opposite effect on ACB stock, albeit in a very different market for marijuana stocks.) Cronos Group (NASDAQ:CRON) is up 47% in 2019; TLRY shares actually have declined 30%. Is There Juice Left in HEXO?So the interesting question here is whether there's more outperformance on the way with HEXO -- or if the market has caught up with the story at this point. Josh Enomoto wrote last month, with the HEXO stock price not far from current levels, that the stock still looked compelling.And Enomoto makes several solid points. The Newstrike deal adds capacity. The combined companies' total production capacity is 150,000 kilograms of cannabis annually.But the company's focus on edibles and beverages -- including a joint venture with Molson Coors Brewing (NYSE:TAP) -- also limits its exposure to oversupply concerns I've previously highlighted.Increasingly, it appears that simply producing weed isn't going to be the path to enormous profits. Cannabis plays need to be differentiated. Hexo's goal of becoming "the premier branded ingredients for food cannabis company", as it put it in a recent presentation, creates that differentiation.At the same time, the gains in HEXO stock have moved its valuation to the nosebleed levels seen elsewhere in the space. Its market capitalization, pro forma for the Newstrike deal, is likely nearing $2 billion. (It's not clear exactly how many shares will be issued to Newstrike shareholders. Hexo's most recent filing with Canadian regulators also cites nearly 50 million shares subject to warrants not included in the current diluted share count of nearly 200 million.) * 6 Trade War Stocks With a Lot of Risk Meanwhile, Q2 net revenue, as impressive as growth was, came in at just C$13.4 million (~$10 million). HEXO stock, then, is trading at something like 50x its current revenue run rate. Just Another Pot Stock?The combination of valuation and trading volume suggests that HEXO no longer is an "under the radar" play. And that makes the case a bit tougher from here.At this point, investors have no shortage of options when it comes to investing in cannabis. And the choice largely comes down to how an investor sees the space playing out. Those looking for scale should choose Canopy or Cronos, both of which are backed with billions of dollars from Constellation Brands (NYSE:STZ) and Altria (NYSE:MO), respectively.Tens of smaller, high-risk plays still sit on over-the-counter markets. Aurora offers the most diversification. Tilray might be getting cheap after its long decline. Another alternative is the 40-pot-stock ETFMG Alternative Harvest ETF (NYSEArca:MJ), which includes HEXO stock among its top 10 holdings, at 3.76% of the portfolio. CRON is the largest holding, at 8.71%.The case for HEXO is intriguing, particularly for those (like Enomoto) who see big growth in edibles and beverages. But the story is out there -- and the edge might not be quite what it was just a few months ago.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post After Investors Ignored It, Is Hexo Stock Now Getting Too Much Attention? appeared first on InvestorPlace.
By acquiring Delaware craft brewer Dogfish Head for $300 million, Boston Beer won more than just growth. Perhaps, it's found a successor.
For the 30 of us on History Colorado's advisory committee — brewers, writers, breweriana collectors and others — the first task was identifying the key events and players that told the tale of 160 years of beer in the state.
Cannabis cultivation requires enormous amounts of energy, and water, and the companies that employ smart solutions are now pulling ahead in the highly competitive cannabis boom
The top beer stocks have a market cap exceeding $2 billion and are trading on leading American stock exchanges. Here are the top beer stocks of 2018.
Molson Coors Brewing Co NYSE:TAPView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for TAP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.49 billion over the last one-month into ETFs that hold TAP are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. TAP credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The government can decline to enforce antitrust legislation, allowing mergers to occur until a few players dominate an industry. In their disturbing tour through the economy, Tepper and Hearn show that consumers and workers must contend with oligopoly, duopoly, and monopoly structures in many industries. Drug companies, for example, live off patents, and adjust chemical formulae to extend those protections indefinitely. Online advertising is owned by Google (GOOGL) and Facebook (FB) while Google has quashed or hampered businesses in “narrow search” such as Foundem and Yelp without punishment.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...
The iPhone maker beat Wall Street's first quarter profit forecasts and raised its quarterly dividend. The drugstore operator blew past first quarter profit estimates and raised its profit forecast for the year. The cruise line operator had more passengers boarding its ships during the first quarter, pushing profit above Wall Street's forecasts.
Stocks close lower Wednesday, following a press conference by Fed Chair Jerome Powell, during which he played down the significance of falling inflation rates
The end of April and the beginning of May isn't just a transition from one month to the next. For investors, the turn of the calendar between these two particular months marks an end to the best six months of the year for stocks and a move to the weakest six months of the year. The whole "sell in May" thing is rooted in reality.Just because the broad tailwind has stopped blowing, however, doesn't necessarily mean every stock is ready to stagnate here. It just means investors should be more selective than they might normally be. * 7 Stocks That Are Soaring This Earnings Season With that as the backdrop, here's a rundown of some of the top stocks to buy -- rather than sell -- as the month of May gets going. These picks have demonstrated some sort of edge headed into this slow time of year. Either there's budding technical bullishness in play, or extreme value, or in many cases, both. In no particular order…InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molson Coors Brewing (TAP)Beer giant Molson Coors Brewing (NYSE:TAP), the company behind brands like Bergenbier, Blue Moon and of course Molson, had a rough go of things between late-2016 and late 2018. All told, TAP stock fell more than 50% from peak to trough in response to a sales slowdown that ended up crimping earnings.Challenges remain. So do doubts. Two years of misery will force a company to regroup, though, and without saying as much, enough bulls have plowed in at recent long-term lows to snap Molson Coors shares out a well-framed downtrend and back above the 200-day moving average line for the first time since early 2017.The kicker: Revenue is expected to stabilize next year, reversing the earnings decline. That is, this year's projected profit of $4.76 per share is forecasted to grow to $4.92 per share next year. That appears to be just enough to spur some new bullishness. DowDuPont (DWDP)DowDuPont (NYSE:DWDP) has been through several structural shakeups over the course of the past few years, with the most recent being the spinoff of Dow (NYSE:DOW) a month ago. Come June 1, the company's agricultural arm Corteva will also be separated from its parent.The breakup has been inspired by the same reason for all corporate splits -- as a means of unlocking value and letting each unit operate without being distracted by other unlike business arms.In this instance, however, there's a nuance that's making DWDP one of the top stocks to by before or after the impending separation of Corteva. That is, traders are already starting to file back into the stock after a rough 2018, suggesting they already realize the upside of the breakup. * 7 Stocks to Buy That Ought to Buy Back Shares Take the hint at face value, particularly if DWDP shares can push above the technical ceiling waiting at $40.43. Expedia Group (EXPE)Years ago, when the internet was still young, the tourism industry struggled to connect with consumers online. Online travel arrangement middlemen like Expedia Group (NASDAQ:EXPE) filled a gap quite nicely.That ceased to be the case a couple of year ago, however. Weary of sharing revenue with players like Expedia, airlines, hotels, car-rental agencies and everyone stepped up their online games and got serious about bypassing online travel agents. Expedia, along with Booking Holdings (NASDAQ:BKNG) and Trivago (NASDAQ:TRVG), were unable to demonstrate their actual value to the customers they were serving.That's starting to change, at least for Expedia, if the chart's recent action is any indication. After a rough 2017 and 2018, we're starting to see higher lows. Better yet, analysts anticipate revenue growth of 10% this year and next year, which should start to drive even more earnings growth now that the company has finally found its place again. Hewlett Packard Enterprise (HPE)Hewlett Packard Enterprise (NYSE:HPE) is, as you'll remember, the business side of the old Hewlett-Packard, which split from the consumer-oriented arm back in 2015.Though "Enterprise" got off to a good start, shares of HPE stock haven't made any net progress since August of 2016. It's not because the company hasn't been doing what it's supposed to do though. While sales growth has been anemic -- and will continue to be so through next year -- Hewlett Packard Enterprise has been able to leverage its leadership in the hybrid cloud arena into better margins. Last year's earnings of $1.56 per share are expected to grow to $1.65 this year, and reach $1.75 per share next year. * 7 A-Rated Stocks That Are Under $10 HPE's hybrid cloud tech is good enough to secure Google as a business partner, setting the stage for an unexpectedly strong 2019. PerkinElmer (PKI)Many investors may have never even heard of PerkinElmer (NYSE:PKI). But, don't mistake a lack of familiarity for a lack of size or strength. It's just a name that's doing a great deal of work behind the front lines of the healthcare world.PerkinElmer is a diagnostics outfit, helping caregivers diagnose and identify all sorts of medical problems. The company even offers environmental and food testing solutions. It's far from a sexy, headline-grabbing business, but it's reliable, and PKE is one of the best stocks to buy in this uncertain environment. Much like the company's top and bottom lines, PerkinElmer's stock's uptrend isn't thwarted for very long.The bullish case is bolstered by the recently reported first-quarter beat, which was followed by upped guidance. Even that may underestimate what's in store, however. For the past 12 quarters, PerkinElmer has only missed estimates twice, and has beat estimates nine of those times. ResMed (RMD)ResMed (NYSE:RMD) shares took one on the chin in January, losing 20% of its value after falling short of its fiscal Q2 revenue projection. The pros were calling for a top line of $673 million, but the company only reported $651 million.In retrospect, however, traders appear to realize they overshot their bearish target. RMD has reclaimed nearly half of what it lost in that one rough day, and the bulls continue to test the waters of higher highs.The pros are getting (back) on board too, with JP Morgan upgrading the stock last month, and Deutsche Bank upgrading it to a "buy" in March. JP Morgan's upgrade in April, in fact, reversed the knee-jerk downgrade the firm dished out on RMD immediately after that ill-fated earnings report. Looking back, JP Morgan's analysts still seem to appreciate this year's and next year's revenue is expected to grow by double-digits. * 7 Cloud Stocks to Buy Now The kicker: This is a bullish time of year for healthcare equipment names like ResMed. These stocks gain, on average, about 5% between early March and late July. Mohawk Industries (MHK)Mohawk Industries (NYSE:MHK) may not be a red-hot growth machine, but it doesn't have to be. Priced at only 11.5 times its forward-looking profit, Mohawk is a solid value prospect.Mohawk, of course, is the flooring company that's been around for ages. At one time only a carpet name, it has since diversified into tile, laminate and even countertops.Shares took a sizable tumble in 2018, falling from a high near $287 to a low around $109 in December of last year. The selloff reflected an admittedly disappointing year, marked by a sharp dropoff in revenue and earnings.The bears arguably hit it a little too hard, though, and this week's strong gains renew a rebound effort that got started in earnest in February. A break above the 200-day moving average line around $143 and the February high around $144.50 would seal the budding deal. Alexion Pharmaceuticals (ALXN)Alexion Pharmaceuticals (NASDAQ:ALXN) isn't exactly a mainstream name, but give it time -- that could change.Alexion's portfolio consists of four drugs, with a handful more in the pipeline. And, it's a perfect mix. Soliris is the breadwinner, driving $3.56 billion in sales last year, but a couple of its other, smaller drug saw sales growth of 40% in 2018. The mix of stability with strong growth translates into widening margins, and this year is shaping up to be a real profit breakout. Driven by almost 16% sales growth, analysts expect per-share earnings to swell from last year's $7.92 to $9.47. * 7 Dividend Stocks That Could Double Over the Next Five Years The stock has been stuck in a sideways range since 2017, but the budding effort to break back above $141 could be catalytic. Retail Properties of America (RPAI)The headlines suggest the so-called retail apocalypse is in full swing. The numbers suggest otherwise. Consumer spending grew 0.9% in March, which was the best single-month improvement in almost a decade. Calm inflation and rising wages are proving to be a real boon, and with the Federal Reserve in no particular hurry to raise interest rates, real estate remains cheap and easy to finance.Enter Retail Properties of America (NYSE:RPAI). This retail real estate investment trust (or REIT) was on its heels for the better part of 2017 and 2018, with investors concerned the company was on the wrong side of two different but related trends… interest rates and slowing retail consumption.Now, however, the bulls are quietly toying with a turnaround. A move above the technical ceilings at $13 and then $13.30 could prove game-changing. Hologic (HOLX)Finally, add Hologic (NASDAQ:HOLX) to your list of stocks to buy in May.Hologic is another diagnostics and testing name. Like most other organizations in the industry, red-hot growth isn't in the cards, but steady progress is. Only once since 2010 has the company failed to drive year-over-year quarterly sales growth.Though not without its ups and downs, the stock's long-term history reflects this consistency. * 7 Stocks That Are Soaring This Earnings Season The action seen over the course of just the past few days, though, makes HOLX a compelling prospect right now. After rushing higher early this year and developing an overbought condition by March, profit-takers dug in. It was where and how the rebound took shape that's telling. All it took was a kiss of the pivotal 200-day moving average line to rekindle the rally effort. The steep stumble simply hit the 'reset' button and cleared the decks for what could end up being a lengthy climb.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 Stocks That Are Soaring This Earnings Season * 5 Biotech Stocks for a Long-Lived Portfolio * 10 Times Apple's Hardware Failed Consumers -- And Hurt Its Business Compare Brokers The post The 10 Best Stocks to Buy for May appeared first on InvestorPlace.
Molson Coors Brewing Co. tried to hype up its Miller Lite and Coors Light brands on Wednesday, but its efforts fell flat.